SCHEMBL7183859

SCHEMBL7183859

CC(C)(C)OC(=O)N1CC[C@H](n2c(=O)[nH]c3cc(C(F)(F)F)cnc32)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.47
PIK3CA P42336 1/20 0.43
NR3C1 P04150 1/20 0.42
PIK3CD O00329 1/20 0.41
STS P08842 1/20 0.41
HCAR1 Q9BXC0 1/20 0.40
EGFR P00533 3/20 0.40
TNF P01375 2/20 0.40
LITAF Q99732 2/20 0.40
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
SRC P12931 3/20 0.39
HDAC4 P56524 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HPGDS O60760 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
TACR1 P25103 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183866 1.00 HSD11B1 (0.47) HSD11B1PIK3CANR3C1PIK3CDSTS
SCHEMBL23253207 0.87 HSD11B1 (0.49) HSD11B1PIK3CAPIK3CDHCAR1EGFR
SCHEMBL2636724 0.87 HSD11B1 (0.59) HSD11B1PIK3CANR3C1PIK3CDHCAR1
SCHEMBL23253206 0.87 HSD11B1 (0.49) HSD11B1PIK3CAPIK3CDHCAR1EGFR
SCHEMBL2636722 0.87 HSD11B1 (0.59) HSD11B1PIK3CANR3C1PIK3CDHCAR1
SCHEMBL21811052 0.86 HSD11B1 (0.45) HSD11B1PARP1PARP2MAPT
SCHEMBL21811053 0.86 HSD11B1 (0.45) HSD11B1PARP1PARP2MAPT
SCHEMBL23253093 0.85 HSD11B1 (0.47) HSD11B1PIK3CAPIK3CDHCAR1EGFR
SCHEMBL23253094 0.85 HSD11B1 (0.47) HSD11B1PIK3CAPIK3CDHCAR1EGFR
SCHEMBL7191745 0.83 HSD11B1 (0.52) HSD11B1PARP1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425504-A1 IMIDAZOPYRIDINONE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (assignee) (JP) 2024-12-26 US disclosed
EP-3808747-B1 IMIDAZOPYRIDINONE COMPOUND KISSEI PHARMACEUTICAL (JP) 2024-12-18 EP disclosed
US-12077531-B2 Imidazopyridinone compound KISSEI PHARMACEUTICAL CO., LTD. (JP) 2024-09-03 US disclosed
CN-112689637-B Imidazopyridone compounds 橘生药品工业株式会社 2023-11-10 CN disclosed
US-20210206765-A1 IMIDAZOPYRIDINONE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-07-08 US disclosed
EP-3808747-A1 IMIDAZOPYRIDINONE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-04-21 EP disclosed
CN-112689637-A Imidazopyridinone compounds 橘生药品工业株式会社 2021-04-20 CN disclosed
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed
EP-1196391-A1 BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-17 EP disclosed
WO-2001005770-A1 BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077531-B2 Imidazopyridinone compound EGLN3, DHPS, EGLN2 HSD11B1 304/4885PIK3CA 2628/4885NR3C1 1059/4885
US-20240425504-A1 IMIDAZOPYRIDINONE COMPOUND EGLN3, DHPS, EGLN2 HSD11B1 304/4885PIK3CA 2628/4885NR3C1 1059/4885
US-20210206765-A1 IMIDAZOPYRIDINONE COMPOUND DHPS, EGLN3, P4HA1 HSD11B1 216/4885PIK3CA 2929/4885NR3C1 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.